Modulation Of Airway Reactivity With Chronic Mechanical Strain

Not Applicable

Completed

• Conditions: Asthma
• Interventions: Device: Continuous Positive Airway Pressure (CPAP); Device: Continuous Positive Airway Pressure (CPAP) Sham

• Registration Number: NCT02396849
• Lead Sponsor: Indiana University

Brief Summary

The purpose of this study is to see if the use of a machine called CPAP will help children with asthma breathe better. CPAP is a machine that produces airflow to help people with breathing problems. To use it, you will wear a mask connected by a hose to the CPAP machine. We believe that use of CPAP may be a treatment for children with asthma.

Detailed Description

During the previous funding period of this project, our laboratory demonstrated that chronic mechanical strain imposed on the airways in vivo using continuous positive airway pressure (CPAP) results in a dramatic reduction in airway reactivity in vivo in mice, ferrets and rabbits1-3. Lungs, airways and airway smooth muscle (ASM) tissues isolated from CPAP-treated animals studied in vitro exhibited lower responsiveness to bronchoconstrictors1-3. We also observed this suppression of airway responsiveness by chronic mechanical strain in a rabbit model of allergic asthma5. These animal studies led to a small clinical trial in which adults with asthma were treated with nocturnal CPAP for 1 week. CPAP caused a significant reduction in airway reactivity in these patients6. This novel approach for treating airway hyper-reactivity is currently being evaluated in a NIH multi-center Phase II clinical trial of adults with mild to moderate asthma (U01 HL108730).

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2015-01
• Study First Submitted: 2015-03-18
• Study First Submitted QC: 2015-03-23
• Study First Posted: 2015-03-24
• Primary Completion: 2020-01-09
• Study Completion: 2020-01-09
• Results First Submitted: 2021-01-05
• Results First Submitted QC: 2021-01-27
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-17
• Results First Posted: 2021-02-18
• Last Update Posted: 2021-03-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

• Children 8-17 yrs olds with severe asthma (N=120) will be recruited from the Pediatric High Risk Asthma Clinic and Pulmonary Clinics at Riley Hospital for Children at Indiana University Health.
• Severe asthma will be defined by the need for medication therapies following steps 4-6 according to the National Institutes of Health's Asthma Care Quick Reference, September 2012 or high dose of inhaled corticosteroids
• On a stable regimen of asthma medications for at least 8 weeks prior to enrollment without systemic corticosteroids for ≥ 4 weeks

Read More

Exclusion Criteria

• Obese (>95% predicted BMI)
• Congenital heart disease or chronic lung disease
• History of pneumothorax
• Inability to perform pulmonary function testing
• Oxygen saturation <93%
• forced expiratory volume at one second (FEV1) <70% predicted
• Provocative concentration causing a 20% drop in FEV1 from baseline (PC20) ≥16 mg/ml of methacholine.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Continuous Positive Airway Pressure (CPAP)	Continuous Positive Airway Pressure (CPAP)	Use of a CPAP machine for at least 5 days per week for 28 days
Continuous Positive Airway Pressure (CPAP) Sham	Continuous Positive Airway Pressure (CPAP) Sham	Use of a sham CPAP machine for at least 5 days per week for 28 days

Primary Outcome Measures

Name	Time	Method
Change in Airway Reactivity From Baseline (Visit 1) and 4 Weeks (Visit 2)	baseline (visit 1) and 4 weeks (visit 2)	The change in airway reactivity measured prior to and after 4 weeks of either CPAP or SHAM treatment. Methacholine bronchial challenge was performed using the 5-breath protocol (DeVilbiss646 with KoKo dosimeter: 9 μL/breath) with quadrupling concentrations starting with 0.0625 mg/mL and continuing until FEV1 decreased by 20% (PC20) or Methacholine concentration of 16 mg/mL was inhaled.

Secondary Outcome Measures

Name	Time	Method
Change in Airway Inflammation From Baseline (Visit 1) and 4 Weeks (Visit 2)	baseline (visit 1) and 4 weeks (visit 2)	Airway Inflammation assessed as the change in the percentage eosinophils in the induced sputum measured prior to and after 4 weeks of Continuous Positive Airway Pressure (CPAP) or sham CPAP treatment.

Trial Locations

Locations (1)

Riley Hospital for Children; 🇺🇸 Indianapolis, Indiana, United States